Interferon alpha plus ribavirin tor chronic hepatitis C genotype 1b non-responder patients to interferon alone.

被引：0
|
作者：
Iacono, OL
Castro, A
Diago, M
Cors, R
Borque, MJ
Buey, LG
Monzon, CG
Pedreira, J
Otero, RM
机构：
[1] Univ Autonoma Madrid, Madrid, Spain
[2] Univ Palermo, Madrid, Spain
[3] Hosp Juan Canalejo, A Coru A, Spain
[4] Gen Hosp, Valencia, Spain
[5] Hosp Princess, Madrid, Spain
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
424
引用
下载
收藏
页码：266A / 266A
页数：1
相关论文
共 50 条
  • [31] Response to interferon and ribavirin or interferon alone in chronic hepatitis C genotype Ib infection.
    Clarke, G
    Stewart, S
    McKienan, S
    Cockram, A
    O'Keane, JC
    Kelleher, D
    Crowe, J
    HEPATOLOGY, 1998, 28 (04) : 210A - 210A
  • [32] Interferon plus ribavirin in chronic hepatitis C non-responding to recombinant alpha-interferon.
    Giampaolo, B
    GASTROENTEROLOGY, 2000, 118 (04) : A210 - A210
  • [33] Which is the most cost-effective combination therapy using interferon alfa-2b plus ribavirin for non-responder patients with chronic hepatitis C?.
    Ricardo, MO
    Carmen, A
    Angel, CM
    Leslie, F
    HEPATOLOGY, 2002, 36 (04) : 577A - 577A
  • [34] Interferon plus ribavirin in interferon non-responder or relapsing chronic hepatitis C patients:: End of treatment response and sustained response at third follow-up month.
    Moreno-Monteagudo, JA
    García-Buey, L
    Fernández-Bermejo, M
    Sanz, P
    Borque, MJ
    Lo Iacono, O
    García-Monzón, C
    Moreno-Otero, R
    HEPATOLOGY, 1998, 28 (04) : 476A - 476A
  • [35] The effect of interferon plus ribavirin or interferon alone on the development of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis C
    Yang, HC
    Lai, MY
    Chen, PJ
    Kao, JH
    Chen, DS
    JOURNAL OF HEPATOLOGY, 2002, 36 : 250 - 250
  • [36] Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
    De Ledinghen, V
    Trimoulet, P
    Winnock, M
    Bernard, PH
    Bourliere, M
    Portal, I
    Remy, AJ
    Canva, V
    Levy, S
    Foucher, J
    Chene, G
    Couzigou, P
    HEPATOLOGY, 2001, 34 (04) : 586A - 586A
  • [37] Combination therapy with interferon α-2b/ribavirin plus lactoferrin for chronic hepatitis C in patients with genotype 1b and high viremia.
    Goto, K
    Mima, S
    Kumagai, N
    Tsuchimoto, K
    Ishii, K
    Sumino, Y
    Yamauchi, K
    Teraguchi, S
    HEPATOLOGY, 2002, 36 (04) : 591A - 591A
  • [38] Prospective study on early virologic response to treatment with interferon α-2b plus ribavirin in patients with chronic hepatitis C genotype 1b
    Nagaki, M
    Imose, M
    Naiki, T
    Kimura, K
    Hayashi, H
    Shimizu, M
    Ohnishi, H
    Tomita, E
    Sugihara, J
    Amano, K
    Sakai, T
    Kojima, T
    Katsumura, N
    Kondo, Y
    Fujmoto, M
    Moriwaki, H
    HEPATOLOGY RESEARCH, 2005, 33 (04) : 285 - 291
  • [39] Pegylated interferon plus ribavirin therapy is associated with improvement of the serum adiponectin and insulin resistance in patients with genotype 1b chronic hepatitis C
    Watanabe, Hisayoshi
    Saito, Takafumi
    Katsumi, Tomohiro
    Tomita, Kyoko
    Sato, Chikako
    Ishii, Rika
    Haga, Hiroaki
    Okumoto, Kazuo
    Nishise, Yuko
    Suzuki, Yoshihiro
    Suzuki, Katsunori
    Ishibashi, Masamichi
    Shinzawa, Haruhide
    Ueno, Yoshiyuki
    Kawata, Sumio
    HEPATOLOGY, 2012, 56 : 1017A - 1017A
  • [40] A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy
    Younossi, ZM
    Mullen, KD
    Zakko, W
    Hodnick, S
    Brand, E
    Barnes, DS
    Carey, WD
    McCullough, AC
    Easley, K
    Boparai, N
    Gramlich, T
    JOURNAL OF HEPATOLOGY, 2001, 34 (01) : 128 - 133
12345